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Polo-like kinase 1 (PLK1) is a key regulator of cell di-
vision and is overexpressed in many types of human
cancers. Compared to its well-characterized role in
mitosis, little is known about PLK1 functions in inter-
phase. Here, we report that PLK1 mediates estrogen
receptor (ER)-regulated gene transcription in human
breast cancer cells. PLK1 interacts with ER and is re-
cruited to ER cis-elements on chromatin. PLK1-co-
activated genes included classical ER target genes
such as Ps2,Wisp2, and Serpina3 and were enriched
in developmental and tumor-suppressive functions.
Performing large-scale phosphoproteomics of estra-
diol-treated MCF7 cells in the presence or absence
of the specific PLK1 inhibitor BI2536, we identified
several PLK1 end targets involved in transcription,
including the histone H3K4 trimethylase MLL2, the
function of which on ER target genes was impaired
by PLK1 inhibition. Our results propose amechanism
for the tumor-suppressive role of PLK1 in mammals
as an interphase transcriptional regulator.INTRODUCTION
The steroid hormone estradiol (E2) acting via the estrogen recep-
tor-a (ER) has essential functions in growth and development of
both normal and tumorigenic breast tissue. ER is a nuclear re-
ceptor that mediates its functions through the transcriptional
activation of target genes and by crosstalk with kinase cas-
cades, which activate both receptors (Kato et al., 1995) and tran-
scriptional cofactors (Wu et al., 2004) needed for target gene
activation. Several kinase pathways have been identified as
participants in estrogen-mediated gene regulation, including
ERK/MSK1 (Migliaccio et al., 1996), PI3K/AKT (Castoria et al.,
2001), PKC (Castoria et al., 2004), and IKKa (Park et al., 2005).
Target gene activation by nuclear receptors is a multistep pro-
cess that includes the recruitment of coregulatory proteins to
enhancer and promoter sites on the DNA. Coregulatory proteins
function in chromatin remodeling and histone modification and
as bridging factors to the RNA polymerase II initiation complexCto activate or repress gene transcription (Kato et al., 2011). The
two main classes of histone-modifying enzymes are histone
acetyltransferases and methyltransferases together with their
enzymatic counterparts. For instance, ER-activated genes are
commonly associated with elevated levels of trimethylation on
H3K4 (H3K4me3) (Mo et al., 2006), increased acetylation of
several lysine residues on H3 and H4 (Me´tivier et al., 2003),
and decreased levels of the repressive histone mark H3K9me3
(Shi et al., 2011). Kinases can also directly act as steroid receptor
cofactors to locally modify other transcriptional regulators as
well as chromatin components (Vicent et al., 2006; Devaiah
et al., 2012).
The serine/threonine kinase Polo-like kinase 1 (PLK1) is a key
regulator of mitotic cell division and is overexpressed in many
types of human cancers, including breast cancer (McInnes and
Wyatt, 2011). Conversely to its accepted role as proto-onco-
gene, evidence exists for an additional tumor-suppressive role
of PLK1. PLK1 knockout mice are early embryonic lethal, while
heterozygous knockout mice developed tumors at a 3-fold-
higher frequency than wild-type mice, indicating a role of PLK1
in early development and tumor suppression (Lu et al., 2008).
Genetic screens of cancer cell lines further identified several
mutations in the PLK1 gene that impaired its function (Simizu
and Osada, 2000). The molecular mechanisms involved in these
tumor-suppressive roles of PLK1 are unknown.
We report here that PLK1 regulates estrogen-mediated gene
expression by interaction with ER and corecruitment to ER target
sites on chromatin.We also identified ER-independent transcrip-
tional effects. Both ER-dependent and ER-independent PLK1
functions have tumor-suppressive properties, as indicated by
correlation analysis to a published breast cancer cohort. Global
phosphoproteomic analysis of PLK1 targets in interphase breast
cancer cells identified several coregulatory proteins as well as
transcription factors that potentially mediate ER-dependent
and ER-independent transcriptional functions, providing a valu-
able resource for future studies on breast cancer physiology.RESULTS
PLK1 Coregulates Estrogen-Mediated Gene Expression
As expression levels of PLK1 and ER were previously shown to
be correlated in breast cancer (Wolf et al., 2000), we wondered
whether a functional relationship exists between both proteins.ell Reports 3, 2021–2032, June 27, 2013 ª2013 The Authors 2021
Figure 1. PLK1 Coactivates ER Target Gene
Expression
(A) Hormone-deprivedMCF7 cells were pretreated
with 100 nM BI2536 or vehicle (DMSO) for 1 hr,
followed by induction with E2 (10 nM) or EtOH for
6 hr. Gene-specific mRNA expression levels were
measured by quantitative RT-PCR (qRT-PCR) and
normalized to Gapdh expression and are repre-
sented as relative values to the vehicle control.
(B) Scheme depicting the different inhibitory
modes of BI2536 and Poloxin on PLK1.
(C) Gene expression analysis as in (A) but with
cells pretreated for 1 hr with 25 mM Poloxin.
(D) MCF7 cells were transfected with siRNA
against PLK1 or control siRNA, sorted for different
cell-cycle phases, and PLK1 mRNA expression
levels analyzed by qRT-PCR.
(E) siRNA-transfected MCF7 cells were induced
for 6 hr with E2 or EtOH control and subsequently
sorted for different cell-cycle phases. Gene-spe-
cific mRNA expression levels were measured by
qRT-PCR and normalized to Gapdh expression
and are represented as relative values to the
G1/G0 vehicle control.
(F) Hormone-deprived and serum-starved T47D-
MVTL cells were pretreated with 100 nMBI2536 or
DMSO for 1 hr, followed by induction with R5020
or EtOH for 6 hr, and gene expression levels
analyzed by qRT-PCR. Error bars represent SEM
of three independent experiments.
See also Figure S1.To study whether PLK1 affects ER-dependent gene transcrip-
tion, we treated MCF7 cells with the PLK1 inhibitor BI2536 or
vehicle, followed by induction with E2 for 6 hr. Subsequent anal-
ysis of messenger RNA (mRNA) levels by quantitative RT-PCR
(qRT-PCR) revealed a clear E2-mediated induction of classical
ER target genes, including Greb1, Sgk1, Ps2, Serpina3, Wisp2,
and Xbp1, in the control cells (Figure 1A). Notably, in the pres-
ence of BI2536, the induction of Greb1, Sgk1, Ps2, Serpina3,
and Wisp2 was strongly reduced, while Xbp1 was only slightly
affected (Figure 1A).
The inhibitor BI2536 is an ATP analog that inhibits PLK1 by
binding to its catalytic domain and preventing binding of ATP
(Steegmaier et al., 2007). To exclude the possibility of a nonspe-2022 Cell Reports 3, 2021–2032, June 27, 2013 ª2013 The Authorscific effect of BI2536 on other kinases, we
repeated the experiments using the PLK1
inhibitor Poloxin, which blocks the Polo
box domain needed for the interaction of
PLK1 with its substrates (Figure 1B)
(Reindl et al., 2008). Treatment of MCF7
cells with Poloxin inhibited E2-mediated
induction of the same set of genes and
to a similar extent, as observed for
BI2536, but only slightly affected the in-
duction of Xbp1, indicating that PLK1
functions as a target-gene-specific ER
coactivator (Figure 1C).
Although both inhibitors are highly spe-
cific to Polo-like kinases, they are alsoable to inhibit the PLK1 isoforms PLK2 (SNK) and PLK3 (FNK)
(Steegmaier et al., 2007; Reindl et al., 2008). To verify that our
observed effects were due to inhibition of PLK1 and not other
PLK isoforms, we reduced PLK1 levels with PLK1-specific small
interfering RNA (siRNA) (Figure 1D). Under these conditions,
about 45% of the cells arrested in G2/M phase due to the lack
of mitotic signaling of PLK1 (Figures S1A and S1B). In order to
evaluate the effect of PLK1 knockdown on gene expression
without the possibility of cell-cycle-dependent expression
changes, we sorted cells according to their cell-cycle phase after
induction with E2 for 6 hr (Figure S1B). In accordance with its
mitotic expression profile, PLK1 expression was 25-fold higher
in G2/M compared to G1 (Figure S1C). In the presence of
PLK1 siRNA, PLK1 expression levels were effectively reduced in
both cell-cycle phases (Figures 1D and S1A). Analyzing the
expression of ER target genes that were sensitive to pharmaco-
logical PLK1 inhibition, we observed a strong reduction of
E2-mediated gene induction in both G1 and G2/M populations
of MCF7 cells (Figure 1E). While induction of Ps2, Greb1,
SerpinA3, and Sgk1 were affected in both cell-cycle phases,
the E2-mediated upregulation of Xbp1 expression was only
affected in G2/M phase and the expression of Pgr was not
affected by PLK1 knockdown (Figure 1E). In addition, siRNA-
mediated knockdown of PLK2 or PLK3 in nonsorted MCF7 cells
did not affect estrogen-mediated gene induction (Figures S1D
and S1E). Taken together, these results further support the
target-gene specificity of PLK1 action on E2-regulated gene
transcription and support a direct effect of PLK1 signaling on
the coactivation of ER target genes independently of the cell-
cycle phase.
As a further proof of the ability of PLK1 to coactivate steroid
receptor target genes, we also analyzed the effect of PLK1 inhi-
bition on the induction of progesterone receptor (PR) target
genes in T47D-MVTL breast cancer cells that carry a single
copy of the MMTV promoter driving the luciferase gene (Truss
et al., 1995). Treating T47D-MVTL cells for 6 hr with the
synthetic progesterone analog R5020 in the presence or
absence of BI2536, we observed that the induction of several
PR target genes, including Stat5a, Hsd2, Cxcl12, Phf8, Krt4,
and Mmp25, was strongly reduced (Figure 1F). Conversely,
the induction of the MMTV promoter was not influenced by
BI2536, indicating a target-gene-specific role of PLK1 rather
than a general inhibition of the receptor also in the case of
PR. As a control, the PR protein expression level was not
affected by BI2536 (Figure S1F).
PLK1 Is Recruited to Estrogen Receptor Target Sites on
Chromatin
To explore whether PLK1 acts at the level of chromatin, we per-
formed chromatin immunoprecipitation (ChIP) experiments with
MCF7 cells before and after 5, 30, and 60 min of E2 treatment.
PLK1was specifically recruited to estrogen responsive elements
(ERE) in promoter or enhancer regions of Ps2,Greb1,Wisp2, and
Serpina3 as early as 5 min after hormone addition with similar
kinetics as ER (Figure 2A). While PLK1 binding was maximal at
30min of E2 treatment, it decreased toward 60min for all binding
sites. Meanwhile, we did not observe binding of PLK1 to a pro-
moter proximal region in the gene body, indicating that the bind-
ing was specific to ER target sites (Figure 2A).
The similarity in the kinetics of PLK1 and ER recruitment to
chromatin prompted us to analyze whether ER and PLK1 phys-
ically interact. We immunoprecipitated endogenous ER and
immunoblotted for PLK1. Compared to the immunoglobulin G
(IgG) control, PLK1 coimmunoprecipitated specifically with ER
in a hormone-independent manner (Figure 2B). To assess
whether PLK1 is corecruited to chromatin via ER, we performed
a re-ChIP experiment (Figure 2C). In the presence of E2 treat-
ment, the ER-PLK1 complex was 18.4-fold enriched at the
Ps2 promoter and 3.7-fold enriched at the Greb1 ERE
compared to both the nontreated cells and the ER-IgG control
(Figure 2C). Likewise to the regular ChIP, the signal was spe-Ccific for EREs, while we did not observe binding to the
gene body.
As an additional proof of a combined function of ER and PLK1,
we performed localization studies for both proteins using spe-
cific antibodies against the active phosphorylated forms of ER
(pS118) and of PLK1 (pT210) (Kato et al., 1995; Jang et al.,
2002). Notably, in a large subset of ER-positive cells, we also
observed a clear nuclear signal for active PLK1 (Figure 2D). We
conclude from these results that the interplay of ER and PLK1
takes place in the nucleus and that nuclear PLK1 is catalytically
active.
PLK1-Dependent Genes Are Enriched in Developmental
Functions
To investigate the physiological role of PLK1 coactivation of ER
target genes in breast cancer cells, we analyzed the effect of
PLK1 on the E2-mediated transcriptional response at the global
level. Using MCF7 cells treated for 6 hr with E2, we identified
638 upregulated genes and 498 downregulated genes. Pretreat-
ment of cells with the PLK1 inhibitor BI2536 significantly in-
hibited the induction of 33% of E2-responsive genes (Figure 3A).
Using gene ontology (GO) and Kyoto Encyclopedia of Genes
and Genomes (KEGG) analysis, we observed that those genes
were significantly enriched in developmental functions, while
PLK1-independent E2-responsive genes were enriched for
genes involved in cell-cycle and cancer pathways (Figure 3B;
Table S1).
As in cancer biology developmental genes often act as tumor
suppressors, we wondered whether PLK1-dependent E2-
induced genes are involved in tumor suppression. To answer
this question, we integrated the gene set with a previously pub-
lished cohort of breast cancer samples from 268 tamoxifen-
treated breast cancer patients (Loi et al., 2007) (Figure 3C). Out
of 213 PLK1-dependent E2-induced genes, twice as many
genes correlated with positive clinical outcome than with a nega-
tive outcome (Figure 3C). On the other hand, PLK1-independent
E2-induced genes preferentially correlated with a negative
clinical outcome (Figure 3C), supporting the results of the GO
analysis. Moreover, breast cancer patients with high average
expression of the PLK1-dependent E2-induced gene set had a
clear clinical benefit as compared to patients with low expres-
sion (p = 0.017, hazard ratio [HR] = 0.47) (Figure 3D). Conversely,
E2-upregulated genes that were not sensitive to BI2536 did not
have any clinical impact (Figure 3D). To verify this observation,
we also correlated expression of the PLK1-ER-dependent genes
to a previously compiled data set of 1,881 breast cancer patients
with mixed background (Ringne´r et al., 2011) and obtained
similar results (Figure S2A).
We next asked whether PLK1 has additional transcriptional
functions in MCF7 cells aside from its coactivating function
with ER. To this end, we searched our global gene expression
data set for genes that were differentially regulated between
the control and the BI2536-treated cells in the absence of estra-
diol. We identified 370 genes that were upregulated by BI2536
treatment and 874 that were downregulated. Performing GO
enrichment analysis on the BI2536-downregulated gene set,
we identified a significant (p = 4.7E-5) enrichment of proapopto-
tic genes, including Tgfb3, Trail, Gpr109b, and Mcf2l, which weell Reports 3, 2021–2032, June 27, 2013 ª2013 The Authors 2023
Figure 2. PLK1 Is Recruited to ER Target Sites on Chromatin and Interacts with ER
(A) Hormone-deprived MCF7 cells were induced with E2 for the indicated amounts of time, and ChIP assay was performed with specific antibodies against PLK1
and ER or total rabbit IgG. Specific binding was assessed by qPCR amplification of ER binding sites (ERE) or control regions in the promoter proximal gene body.
Binding is represented as the percentage of input. Error bars represent the SEM of three independent experiments.
(B) Endogenous ER and PLK1 interact. Hormone-deprived MCF7 cells were induced with E2 or EtOH for 1 hr, immunoprecipitation was performed with ER or
rabbit IgG, and protein levels were analyzed by western blot.
(C) PLK1 and ER are corecruited at EREs. re-ChIP experiments were performed with the indicated antibodies. Specific cobinding was assessed by qPCR
amplification of ERE or control regions in the promoter proximal gene body. Target regions were amplified by quantitative real-time PCR. Binding is represented
as the percentage of input. Error bars represent the SEM of three independent experiments.
(D) Active ER and PLK1 colocalize in the nucleus. Localization of PLK1-pT210 (green) and ER-pS118 (red) in MCF7 cells after 30 min E2 treatment were
determined by immunofluorescence microscopy. DAPI staining is shown in blue.also validated by qRT-PCR (Figures 3E and 3F). As these genes
were also sensitive to Poloxin, we concluded that the transcrip-
tional effect by PLK1 was specific (Figure S2B). Furthermore, the
average expression of this gene set positively correlated with2024 Cell Reports 3, 2021–2032, June 27, 2013 ª2013 The Authorsclinical outcome in both the tamoxifen-treated patient cohort
as well as the group of 1,881 breast cancer patients, which is
proof of the tumor-suppressive characteristics of this gene set
(Figures 3G and S2C).
Figure 3. PLK1 Regulates Tumor-Suppressive Gene Transcription
(A) Hormone-deprivedMCF7 cells were pretreatedwith 100 nMBI2536 or the vehicle (DMSO) for 1 hr, followed by induction with E2 (10 nM) or EtOH for 6 hr. Cells
were harvested andmRNA levels analyzed by Agilent gene expressionmicroarrays. The fraction of E2-regulated genes that were significantly inhibited by BI2536
is shown.
(B) GO-term enrichment analysis for E2-upregulated, BI2536-inhibited genes using Fisher’s exact test. The entire list of significantly enriched GO terms can be
found in Table S1.
(C) Correlation of E2-upregulated, BI2536-inhibited (left) or BI2536-noninhibited (right) genes with distant metastasis-free survival in a cohort of 268 tamoxifen-
treated breast cancer patients (Loi et al., 2007). Correlations were scored as good (green), poor (red), or nonsignificant (white) using a cutoff of p < 0.05 for each
gene, as determined by recursive portioning (RP) based on a log-ranked (Mantel-Cox) test.
(D) The average expression levels of the E2-upregulated, BI2536-inhibited, or BI2536-noninhibited gene sets were correlated with distant metastasis-free survival
in the same breast cancer cohort used in (C). Patients were ranked according to the average expression values (top 33% versus bottom 33%), after which the
distant metastasis-free survival was determined for both groups. The p value was determined by a log-ranked (Mantel-Haenszel) test, and the hazard ratio (HR)
was determined with the Mantel-Cox method.
(E) GO-term enrichment analysis for BI2536-downregulated and BI2536-nondownregulated genes independent of E2. A complete list of significantly enriched
terms can be found in Table S1.
(F) Hormone-deprived MCF7 cells were treated with BI2536 or vehicle (DMSO) for 7 hr, and gene expression levels were analyzed by qRT-PCR. Error bars
represent SEM of three independent experiments.
(G) Kaplan-Meier plot as calculated in (D) for the BI2536-downregulated and BI2536-nondownregulated gene sets.
See also Figure S2.
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Figure 4. PLK1 Is a Key Component of E2-
Mediated Signaling
(A) Schematic depiction of the experimental setup
for the global phosphoproteome analysis. MCF7
cells were SILAC-labeled in three different pop-
ulations: light (L), medium (M), and heavy (H).
Cells were pretreated for 1 hr with BI2536 (H) or
vehicle (L and M) following stimulation with E2 (M
and H) or EtOH (L) for 30 min. Cells were lysed,
combined, enzymatically digested, and phospho-
peptides were enriched and analyzed by mass
spectrometry.
(B) PLK1 inhibition does not affect phosphorylation
levels of ER in S118. Extracts from the SILAC
experiment depicted in (A) were analyzed by
western blot.
(C) Overlap of E2- and BI2536-regulated phos-
phosites.
(D) Motif-enrichment analysis of E2-upregulated
and BI2536-downregulated class I phosphosites.
For D/E/N/-X-S/T-F: E2 upregulated: p = 1.3E-
04, BI downregulated: p = 3.9E-08, E2 upregu-
lated/BI downregulated: p = 3.0E-05; for S/T-F:
E2 upregulated: p = 8.4-03, BI downregulated:
p = 3.1E-06, E2 upregulated/BI downregulated:
p = 9.8E-05.
(E) Fisher’s test for significantly overrepresented
GO terms (p < 0.05) among BI2536-down-
regulated phosphoproteins.
See also Figure S3.Taken together, we conclude that transcriptional regulation by
PLK1 of both ER-dependent and ER-independent genes in inter-
phase MCF7 cells is tumor suppressive.
Global Phosphoproteome Analysis Reveals Involvement
of PLK1 in Estrogen-Mediated Signaling
After identifying a key role of PLK1 in ER target gene activation,
we decided to explore its involvement in E2-induced signaling in
a global manner using a stable isotope labeling by amino acids in
cell culture (SILAC)-based high-resolution mass spectrometry
approach (Figure 4A) (Ong and Mann, 2007). Western blot anal-
ysis demonstrated that BI2536 did not influence ER activation,
as measured by the level of phosphorylation at S118 (Figure 4B).
Performing two independent experiments, we were able to iden-
tify and quantify 17,448 phosphorylation sites on 3,463 proteins,
with 8,251 phosphosites common to both replicate experiments
(Table S2). Applying a threshold of 1.5-fold regulation that had to
be fulfilled in both replicates, we identified 195 sites that were
upregulated by E2 and 68 that were downregulated (Figure 4C).
Using a similar filter for the effect of BI2536 (ratio H/M), we repro-
ducibly identified 146 sites that were reduced in response to
BI2536 while 80 sites were enhanced, likely due to secondary
effects of PLK1 inhibition on phosphatases (Figure 4C). Notably,
we observed a strong overlap (54 sites) between E2-upregulated
and BI2536-sensitive phosphosites, representing 28% and 40%
of each population, respectively (p = 1.7E-51). This indicates that
PLK1 is involved in a substantial subset of E2-mediated signaling
events and further suggests that E2 has a strong effect on the
PLK1-regulated phosphosites. This mutual regulation is further
evidenced by an 18% overlap of E2-downregulated sites with2026 Cell Reports 3, 2021–2032, June 27, 2013 ª2013 The Authorssites that are enhanced by BI2536 (p = 2.1E-12) and the lack of
a substantial overlap between phosphosites that are either upre-
gulated by E2 and enhanced by BI2536 or downregulated by E2
and reduced by BI2536 (Figure 4C).
To address the specificity of BI2536 inhibition, we performed a
consensus-motif enrichment analysis using Fisher’s exact test
and a sequence window of 15 amino acids after filtering all iden-
tified phosphopeptides for a localization probability of greater
75% (Olsen et al., 2006) (Figure S3E). We included the modified
classical PLK1 motif D/E/N/-X-S/T-F as well as the alternative
motif S/T-F (X represents any amino acid and F represents a
hydrophobic amino acid), both of which were defined in a recent
phosphoproteome study (Santamaria et al., 2011). Both motifs
were highly enriched in the BI2536-sensitive set of phosphoryla-
tion sites, with p values of 1.9 3 108 and 3.1 3 107, respec-
tively (Figures 4D; Table S3). Interestingly, both motifs were
also significantly enriched among the E2-upregulated sites (Fig-
ure 4D; Table S3). Most strikingly, however, the enrichment was
highest in E2-upregulated phosphosites that were inhibited by
BI2536 (Figure 4D; Table S3). These findings support an implica-
tion of PLK1 in E2-mediated signaling. Of note, both PLK1motifs
were also significantly enriched in a SILAC-based phosphopro-
teomic data set of T47D cells stimulated for 5 and 30 min with
R5020 (Figures S3F and S3G), indicating a conserved role of
PLK1 signaling in estrogen and progestin responses.
To gain deeper insight into the biological processes mediated
by PLK1 in interphase breast cancer cells, we performed Fisher’s
exact test for GO terms for proteins containing one or more
BI2536-sensitive phosphorylation sites. As expected, signifi-
cantly enriched terms included those associated with PLK1
Figure 5. PLK1 and Estradiol Signaling Results in Phosphorylation of Transcriptional Regulators
(A) Proteins with E2- and/or BI2536-regulated phosphosites involved in transcriptional regulation. MLL2 S4822 was manually assigned to the E2-upregulated
BI2536-inhibited gene set.
(B–D) Individual phosphosite regulations. Average normalized M/L ratios (blue) and H/L ratios (red) for E2-regulated BI2536-unaffected (B), E2-upregulated
BI2536-downregulated (C), and BI2536-downregulated phosphosites (D). Phosphosites with localization probability below 75% are marked by an asterisk. Error
bars represent the range of two independent experiments.
See also Figure S4.functions, such as ‘‘cell cycle process’’ and ‘‘cytoskeleton orga-
nization’’ (Figure 4E; Table S4). Notably, BI2536-sensitive phos-
phoproteins were also significantly enriched for the term ‘‘cell
differentiation,’’ supporting the role of PLK1 in developmental
processes. On the other hand, proteins containing E2-regulated
phosphorylation sites were enriched in E2-signaling-associated
GO terms, such as ‘‘positive regulation of transcription fromRNA
polymerase II promoter’’ and ‘‘ion transport,’’ but also for ‘‘actinCcytoskeleton organization’’ and ‘‘cell differentiation,’’ similar to
the BI2536-sensitive phosphosite population (Table S5).
PLK1 Targets Include Transcriptional Regulatory
Proteins
We next searched our data set for transcriptional coregulators
and transcription factors that contain one or more regulated
phosphosites (Figure 5A). We first focused on proteinsell Reports 3, 2021–2032, June 27, 2013 ª2013 The Authors 2027
Figure 6. PLK1 Regulates theMLL2-Coacti-
vating Function on ER Target Genes
(A) Hormone-deprived MCF7 cells were trans-
fectedwith siRNAagainstMLL2 (siMLL2) or control
siRNA (siC), andMLL2mRNA levels were analyzed
by qRT-PCR. RNA levels were normalized to
Gapdh expression and represented as relative
values to the control-siRNA transfected cells.
(B) Cells were transfected with siRNA as in (A) and
treated for 6 hr with E2. Gene expression changes
were analyzed by qRT-PCR.
(C) MCF7 cells were treated with BI2536 or vehicle
(DMSO) for 1 hr followed by induction with E2 for
1 hr. Levels of H3K4me3 and ER were measured
by ChIP in proximal promoter regions (top) and ER
target sites (bottom), respectively.
Error bars represent SEM of three independent
experiments.containing E2 upregulated or downregulated phosphosites that
were not affected by BI2536.We identified several known ER co-
factors among this group of proteins, including SRC2, SRC3,
BPTF, MTA, MED9, MED14, and PSF, indicating that our phos-
phoproteome analysis could represent known signaling events
involved in steroid-receptor-mediated transcriptional regulation
(Figures 5A and 5B).
Next, we focused on proteins with E2-upregulated BI2536-
sensitive phosphosites to identify proteins that are potentially
responsible for the coactivating function of PLK1 on ER target
genes, identifying ten proteins with functions in gene regulation
(Figures 5A and 5C). These included the ER coactivator ATAD2
(Zou et al., 2007), the thyroid receptor coactivator TRIP11
(Chang et al., 1997), the nuclear receptor corepressor SHARP
(Shi et al., 2001), the p63 coactivator and transcriptional elonga-
tion factor SSRP1 (Zeng et al., 2002), and the ER-associated his-
tone H3K4 trimethyltransferase MLL2 (Mo et al., 2006). The latter
was reproducibly assigned to the BI2536-affected category by
comparing the fold induction in response to E2 in the presence
or absence of BI2536 (Figure S4A).
We also identified several proteins involved in transcriptional
regulation among the proteins that contain BI2536-regulated2028 Cell Reports 3, 2021–2032, June 27, 2013 ª2013 The Authorsphosphosites that were unaffected by E2
(Figures 5A and 5D). Interestingly, several
of these have known functions in develop-
ment or apoptosis regulation and could
thereforepotentially account for theER-in-
dependent tumor-suppressive transcrip-
tional effects of PLK1 described above
(Figures 3E and 3G). These include the
developmental transcription factor SOX4,
the transcriptional repressor BCL11B, the
apoptosis-antagonizing transcription fac-
tor AATF, and the death-promoting tran-
scriptional repressor BCLAF1 (Figure 5D).
PLK1 Phosphorylation of MLL2
Affects Gene Regulation
The histone-lysine N-methyltransferase
MLL2 is a key regulator of developmentalgenes essential for the early embryonic development of mice
(Glaser et al., 2006). MLL2 interacts with ER and is essential for
the transcriptional activation of ER target genes, including Ps2
(Mo et al., 2006) andGreb1 (Shi et al., 2011). Estrogen-mediated,
PLK1-dependent phosphorylation of MLL2 occurs at S4822,
which has been previously identified by mass spectrometry in
various cell types (Dephoure et al., 2008; Mayya et al., 2009;
Van Hoof et al., 2009). Interestingly, we also identified a strong
induction of this site in a phosphoproteome analysis of T47D
breast cancer cells in response to progestin (Figure S4B), indi-
cating a conserved function in the action of steroid hormones
in breast cancer cells.
Knocking down MLL2 by siRNA transfection (Figure 6A) in-
hibited E2-mediated induction of Ps2, Wisp2, Serpina3, and
Greb1, while it did not inhibit the induction of Sgk1 and Xbp1
(Figure 6B).
The main described function of MLL2 is to catalyze trimethyla-
tion of histone H3 on K4 (H3K4me3), a histone marker linked to
transcriptional activation (Glaser et al., 2006). Having identified
phosphorylation of MLL2 by PLK1, we wondered whether
PLK1 activity would be important for the estradiol-mediated in-
crease in H3K4me3. To this end, we compared H3K4me3 levels
in the presence or absence of PLK1 inhibition using MCF7 cells
that had been induced with E2 for 1 hr or left untreated (Fig-
ure 6C). E2 treatment mediated a 1.8- to 5-fold increase in
H3K4me3 in proximal promoter regions of Ps2, Greb1, WISP2,
and Serpina3. In the presence of PLK1 inhibition, this increase
was strongly reduced for all four genes. Conversely, for the
MLL2-independent ER target gene Xbp1, we did not observe
an increase in H3K4me3 levels in response to hormone
induction.
DISCUSSION
It is well established that the serine/threonine kinase PLK1 is a
key regulator of mitotic cell division, and immunohistochemistry
studies in breast cancer revealed a close correlation between ER
and PLK1 expression levels (Wolf et al., 2000; Takai et al., 2005).
We show here that PLK1 directly modulates estrogen-depen-
dent gene transcription in breast cancer cells. PLK1 physically
interacts with ER and is corecruited to the enhancer elements
of ER-regulated genes.We also found that PLK1 regulates genes
independently of ER. Surprisingly, both ER-dependent and ER-
independent gene sets were enriched in tumor-suppressive
functions, and high expression levels of each gene set correlated
positively with a clinical benefit in breast cancer patients. Phos-
phoproteomics identified several targets for the transcriptional
effects of PLK1, including the histone H3 K4 trimethyltransferase
MLL2 phosphorylated on serine 4822. Although the large size of
MLL2 did not allow us to assess its function in vivo due to tech-
nical limitations, we identified the same S4822 phosphorylation
site to be strongly induced in T47D breast cancer cells in
response to progestin, indicating a conserved role of MLL2
S4822 phosphorylation in the steroid hormone response. How-
ever, we cannot exclude that MLL2 is an indirect target of
PLK1 kinase activity.
Regulation of MLL2 is not the only mechanism through which
PLK1 potentially affects ER-dependent gene transcription. The
E2-mediated transcriptional induction of Sgk1, for instance,
was dependent on functional PLK1 but not on the presence of
MLL2. Interestingly, in breast cancer cells, Sgk1 expression
was reported to depend on the AAA ATPase and bromodo-
main-containing protein ATAD2 (Kalashnikova et al., 2010),
which we identified to be phosphorylated by E2 and to be sensi-
tive to the PLK1 inhibitor BI2536. Thus, the induction of Sgk1
could be due to regulation of ATAD2.
Global gene expression analysis identified 213 E2-induced
genes that depend on PLK1 activity. Although for a set of clas-
sical target genes we proved that the effect of PLK1 inhibition
was direct, we cannot exclude that BI2536-mediated changes
in cell-cycle kinetics are responsible for this effect in some of
the genes.
The observed enrichment of proapoptotic genes among
genes upregulated by PLK1 was unexpected and controverts
previous studies claiming a negative regulatory role of PLK1 on
proapoptotic genes caused by inhibiting the transcriptional
activity of the p53 family members p53 (Ando et al., 2004),
Tap63 (Komatsu et al., 2009), and Tap73 (Koida et al., 2008;
Soond et al., 2008). The discrepancy is likely due to the different
experimental conditions. While in previous studies the transcrip-Ctional effects of PLK1 were assessed by ectopic coexpression of
PLK1 and p53 family members in p53 null-cells or by siRNA-
mediated knockdown of PLK1 in p53 wild-type cells, we tar-
geted the endogenous levels of PLK1 by direct inhibition. If
PLK1 were to negatively influence p53 family members in our
system, then we should have observed effects in the expression
of p53 family target genes. However, the expression levels of the
classical p53 target genes p21, 14-3-3s, and Bax were not
affected by BI2536 treatment (data not shown).
Among genes inhibited by BI2536, we identified the tumor
necrosis factor-related apoptosis-inducing ligand (Trail), which
in leukemic T cells was described to be a major target of the
transcriptional repressor BCL11B (also known as CTIP2) (Gra-
barczyk et al., 2007). Notably, we identified BCL11B among
the PLK1 phosphorylated proteins, with several BI2536-sensi-
tive phosphorylation sites. BCL11B was described to repress
target genes by recruiting the NuRD complex to promoter sites
via direct interaction with the two NuRD complex members
RbAp46 and RbAp48 (Cismasiu et al., 2005; Topark-Ngarm
et al., 2006). Interestingly, the PLK1-dependent double phos-
phorylation site T313, S318 on BCL11B is located within the
protein region identified to interact with RbAp46 and RbAp48
(Topark-Ngarm et al., 2006), while the PLK1-dependent phos-
phorylation site on S772 resides in a region known to be impor-
tant for the interaction of BCL11B with the repressive factor
HP1a (Rohr et al., 2003). PLK1-dependent phosphorylation in
these regions might interrupt the interactions of BCL11B with
the NuRD complex and HP1a, leading to derepression of
BCL11B-repressed genes, including Trail.
Estrogen signaling via ER is key for the growth and develop-
ment of breast cancer cells. Having identified a dependency of
a quarter of E2-induced phosphorylation sites on PLK1, we pro-
pose that PLK1 fulfills a crucial role in the signaling effects of ER.
Our phosphoproteomic study further provides a source of cata-
lytic PLK1 targets in interphase-enriched cells, whereas previous
studies specifically covered mitotic targets of PLK1 (Grosstess-
ner-Hain et al., 2011; Kettenbach et al., 2011; Oppermann
et al., 2011; Santamaria et al., 2011). Althoughwe identified a sig-
nificant enrichment for proteins involved in ‘‘cytoskeleton organi-
zation,’’ these represented only 11% of all PLK1 targets. This
observation is in close agreement with the study of Lowery and
colleagues, who searched for Polo box domain (PBD)-interacting
proteins using U2OS whole-cell extracts (Lowery et al., 2007).
They found that only a small percentage were actually involved
in classical PLK1-related mitotic functions, while the majority of
PBD-interacting proteins were involved in other cellular pro-
cesses, including transcriptional regulation. Using Poloxin to
inhibit the PBD, we have now shown that the PBD has an essen-
tial function in the transcriptional regulatory activity of PLK1.
Identifying a tumor-suppressive role of PLK1 at the level of
gene transcription raises the question of how to reconcile this
with the tumor-progressive properties of PLK1. A possible expla-
nation could be that overexpression of PLK1 drives cells faster
through mitosis, while basal levels of PLK1 are needed to main-
tain a tumor-suppressive transcriptional program. Our findings
therefore request a reconsideration of the role of PLK1 in breast
cancer that takes into account the different levels of expression
of the kinase in different tumor cell populations.ell Reports 3, 2021–2032, June 27, 2013 ª2013 The Authors 2029
EXPERIMENTAL PROCEDURES
Cell Culture and Hormone Treatments
MCF7 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal calf serum (FCS) and standard antibiotics. For
hormonal starvation, MCF7 cells were cultured for 3 days in phenol-red-free
DMEM supplemented with 5% charcoal/dextran-treated FCS. T47D-MVTL
cells were cultured and hormone deprived as described previously (Vicent
et al., 2006). Cells were induced with E2 (10 nM), R5020 (10 nM), or vehicle
(ethanol) for the indicated times. For knockdown experiments, siRNAs were
transfected using Lipofectamine 2000 at day 1 of the starvation process. Con-
trol and PLK1 knockdown cells were harvested after hormone induction,
stained with DAPI, and sorted by flow cytometry into G0/G1 and G2/M cell
populations based on their DNA content.
RNA Extraction and RT-PCR
RNA was extracted with the RNeasy extraction kit (QIAGEN). Complementary
DNA (cDNA) was generated from 100 ng of total RNA with the First Strand
cDNA Superscript II Synthesis kit (Invitrogen) and analyzed by quantitative
PCR (qPCR). Gene-specific expression levels were regularly normalized to
Gapdh expression. Primer sequences are listed in Table S6.
Coimmunoprecipitation
Cells were lysed in immunoprecipitation buffer (50 mM Tris-HCl [pH 7.4],
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 5 mM MgCl2, 0.5% Triton-X), pro-
tease inhibitor cocktail, and phosphatase inhibitors for 30 min at 4C.
Extracts were cleared by centrifugation and incubated overnight with anti-
ER or normal rabbit IgG bound to protein A Dynabeads. Immunoprecipitated
material was washed four times with Tris-buffered saline and analyzed by
western blot.
ChIP and Re-ChIP Assays
ChIP assays were performed as described elsewhere (Strutt and Paro, 1999),
with minor modifications. Cells were crosslinked in medium containing 1%
formaldehyde for 10 min at 37C. Crosslinking was quenched with 125 mM
glycine for 5 min at room temperature. Cells were washed twice with PBS
and collected by scraping in PBS supplemented with protease and phospha-
tase inhibitors on ice. Cells were lysed in hypotonic buffer and centrifuged and
the pellet containing crude nuclei was lysed with SDS-lysis buffer. Chromatin
was sheared by seven 30 s cycles in a Bioruptor (Diagenode). Around 20 mg of
chromatin (DNA content) was diluted at least 10-fold with ChIP buffer and incu-
batedwith 5 mg of antibody overnight. Immunocomplexes were recoveredwith
40 ml of protein A agarose bead slurry for 2 hr with rotation and washed three
times with ChIP buffer and once with ChIP buffer containing 500 mM NaCl.
Eluted DNA complexes were incubated at 65C overnight, and purified DNA
was analyzed by qPCR. Primer sequences are listed in Table S6.
For the re-ChIP assays, after the washes of the first immunoprecipitation
using ER or rabbit IgG antibodies, the immunocomplexes were eluted with
10 mM DTT at 37C for 30 min, diluted 50-fold with ChIP buffer, and immuno-
precipitated with PLK1 or rabbit IgG antibodies.
Agilent Gene Expression Profile and Gene Ontology
Labeled complementary RNA was hybridized to the Agilent Human whole
genome 4X44k v2 microarray according to the manufacturer’s protocol.
Intensity data were extracted using Feature Extraction software (Agilent)
and processed using the Agi4x44PreProcess-package of the Bioconductor
project in the R statistical environment. Differential expression analysis was
carried out on noncontrol probes with an empirical Bayes approach on linear
models (limma) (Smyth, 2004). Results were corrected for multiple testing
according to the false discovery rate (FDR) method (Benjamin-Hochberg). A
cutoff of 1.5 and an FDR of 0.01 were chosen to analyze the regulation of
gene expression. To address the effect of BI2536 on ER-mediated gene in-
duction, the contrasts of regulation by E2 in the presence and absence of
BI2536 were required to be 1.3-fold different with a p value <0.05. GO data
were generated using the DAVID Bioinformatics Resources 6.7 (Huang
et al., 2009).2030 Cell Reports 3, 2021–2032, June 27, 2013 ª2013 The AuthorsGene Expression Data from Human Breast Tumors
The microarray data set from 268 tamoxifen-treated patients was obtained
from a previous study (Loi et al., 2007). All data were normalized previously
by robust multiarray analysis. The preprocessed 1,881-sample breast tumor
data set was previously described (Ringne´r et al., 2011). For the integrated
expression analysis, patients were ranked for the average expression of the
studied gene set and top 33% versus bottom 33% analyzed for distant metas-
tasis-free survival according to Zwart et al. (2011). The p values for Kaplan-
Meier curves were calculated with a log-rank test (Mantel-Haenszel), and the
corresponding HR was determined by the Mantel-Cox method.
SILAC Phosphoproteomics
SILAC-labeled MCF7 cells were cultured for 3 days in SILAC media without
phenol red supplemented with 5% charcoal-treated dialyzed FCS. The
unlabeled and the two metabolically labeled cell populations were tested indi-
vidually for their ability to respond to E2 by measuring the levels of ER S118
phosphorylation without the detection of any difference (Figure S3B). Cells
were treated with BI2536 (100 nM) or vehicle (DMSO) for 1 hr followed by
induction with E2 (10 nM) or vehicle (ethanol) for 30 min. Cells were harvested
on ice in PBS and lysed in modified RIPA buffer containing protease and phos-
phatase inhibitors. Extracts were separated by centrifugation. Proteins in the
supernatant were acetone precipitated overnight and redissolved in urea
buffer supplemented with phosphatase inhibitors. The insoluble pellet was
resuspended in urea buffer with phosphatase inhibitors and benzonase and
extracted under rotation at room temperature. Extracts of soluble and pellet
extracts were eachmixed in a 1:1:1 (w:w:w) ratio, reduced, alkylated, and sub-
sequently digested with endoproteinase Lys-C and trypsin. Desalted peptides
were separated by strong cation exchange chromatography and enriched for
phosphorylated peptides using TiO2 beads. Peptides were desalted on C18
StageTips, dried to almost completeness, and reconstituted in 4%FA for liquid
chromatography-tandem mass spectrometry (LC-MS/MS) analysis.
The peptides were analyzed on an Orbitrap Velos mass spectrometer
(Thermo Fisher Scientific) linked to an online nanoflow high-performance
liquid chromatography (HPLC) system via a nanoelectrospray ion source
and fragmented via higher-energy C-trap dissociation (HCD) (Nagaraj et al.,
2010).
Bioinformatic Analysis of Phosphoproteome Data
Raw data were processed with MaxQuant software (volume 1.2.2.5) and pro-
cessed as per the standard workflow previously described (Cox et al., 2011;
Geiger et al., 2012). Bioinformatic analysis was performed using Perseus soft-
ware (volume 1.2.0.17). For identification of regulated phosphosites, a
threshold of 1.5-fold regulation was used, which had to be fulfilled in both repli-
cate experiments. Regulation by E2 was measured using normalized M/L
ratios, and regulation by BI2536 was measured using normalized H/M ratios.
If a peptide contained several phosphorylation sites, regulatory information
was included for all possible phosphorylation states. For motif-enrichment
analysis, phosphosites were filtered for a localization probability >0.75 to
qualify them as class I sites (Cox et al., 2011) (Figure S3E), and Fisher’s exact
test was performed for regulated phosphosites respective to all measured
phosphosites. For GO-term enrichment analysis, Fisher’s exact test was
applied for all regulated phosphosites compared to all measured phosphosites
at the protein level.
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